Methylphenidate may inhibit the metabolism of clomipramine. Downward dose adjustments may be required and plasma drug concentration should be monitored.
Source: NLP:dexmethylphenidate hydrochloride
9 interactions on record
Methylphenidate may inhibit the metabolism of clomipramine. Downward dose adjustments may be required and plasma drug concentration should be monitored.
Source: NLP:dexmethylphenidate hydrochloride
Concomitant use may result in serotonin syndrome with serious CNS reactions, potentially fatal.
Source: NLP:methylene blue
Co-administration can cause severe, prolonged hypertension. Monitor for hypertension if norepinephrine bitartrate cannot be avoided.
Source: NLP:norepinephrine bitartrate
Elimination of clomipramine may be prolonged by armodafinil via inhibition of metabolic enzymes, resulting in higher systemic exposure. Dose reduction may be required.
Source: NLP:armodafinil
Methylphenidate may inhibit metabolism of this tricyclic drug. Downward dose adjustments may be required and plasma concentrations should be monitored.
Source: NLP:methylphenidate
Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol, decreasing cardioselectivity.
Source: NLP:metoprolol
Potent CYP2D6 inhibitor may increase metoprolol plasma concentration, decreasing cardioselectivity.
Source: NLP:metoprolol tartrate
Drug-drug interaction study showed increase in euphoria and postural hypotension in patients who switched to SAVELLA.
Source: NLP:milnacipran hydrochloride
Elimination may be prolonged by modafinil with resultant higher systemic exposure. Dose adjustment may be necessary when used concomitantly.
Source: NLP:modafinil